Follow-up studies of a Roche breast cancer drug have shown that it failed to slow tumour growth or help patients live longer.
This content was published on
1 minute
This could lead to the drug Avastin being taken off of the American market, as US government health scientists announced on Friday.
The Food and Drug Administration (FDA) approved Avastin in 2008, basing its decision on early-stage trials.
However, follow-up studies done by Swiss pharmaceutical giant Roche indicate that the drug does not significantly extend lives when compared with chemotherapy alone.
According to the FDA, more recent data showed that patients experienced more side effects like high blood pressure and fatigue.
On Tuesday the FDA will ask a panel of cancer experts to review the study results.
The FDA may ultimately decide to withraw its approval for Avastin, which was Roche’s top-selling cancer drug in 2009 — with global sales of $5.9 million (SFr6.2 million).
swissinfo.ch and agencies
Popular Stories
More
Foreign affairs
European nations snub Swiss-made weapons over Ukraine restrictions
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss pharmaceutical duo “best in global class”
This content was published on
Having trailed behind Roche over the last few years, Novartis appeared to have turned a corner with a record-breaking performance in 2009. Roche is tipped to amply recoup the acquisition costs that dented its 2009 profits. Both Basel-based firms are standing on solid foundations and are poised to reap strong benefits in the next two…
This content was published on
Roche received two “shame” prizes at the Public Eye Awards in Davos for conducting research on transplant patients in China without knowing the origin of the organs donated. The Basel-based company won the 2010 Swiss Award in addition to the People’s Award – the latter based on an online poll. The presentation is held each…
This content was published on
The deal, announced on Wednesday, aims to accelerate the study of two powerful anti-cancer drugs to improve early cancer treatment. In a statement from its headquarters in Basel, Roche said the accord would promote studies combining its Herceptin drug with the Taxotere drug, which was discovered, developed and marketed globally by Aventis. Roche’s Herceptin was…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.